- Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs
- The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria’s own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands
- The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery
- Lexaria also recently announced an agreement with Ireland’s Anodgen Bioceuticals that allows Anodgen to manufacture and distribute DehydraTECH processed cannabinoid API powders within Europe including the UK, Australia and New Zealand
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has built the reputation of its patented DehydraTECH drug delivery technology through a growing data set of potential medicinal applications and through an expanding list of licensing agreements with third-party companies interested in its potential for cannabidiol (“CBD”)-based products.
Lexaria’s patented DehydraTECH technology transforms a wide variety of orally and topically administered products into enhanced solutions that make the APIs more rapidly available and effective at lower doses while adding zero chemical byproducts.
Among the licensing partnerships announced by the company are recent agreements with beverage developer BevNology and Ireland API manufacturer and distributor Anodgen Bioceuticals.
The BevNology collaboration was announced June 21 and not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand, but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta.
“These agreements build on a long standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” Lexaria CEO Chris Bunka stated in announcing the BevNology development (https://cnw.fm/6it3Q). “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.”
The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer packaged-goods brands. Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility.
The licensing agreement addresses powdered DehydraTECH formulations and liquid formulations that tend toward BevNology’s particular expertise. Both elements of the agreement are non-exclusive, except that the liquid formulations have limited exclusivity in the United States and complete exclusion in Japan, the Republic of Korea, and the People’s Republic of China.
The Anodgen licensing agreement was announced earlier in the month and includes a five-year non-exclusive DehydraTECH license for powdered CBD-based products in Europe including the United Kingdom, Australia, and New Zealand.
Under the license, Anodgen can use DehydraTECH not only for making and selling medical application CBD products but also pharmaceutical applications for psychoactive cannabinoids (https://cnw.fm/JjYBn). Anodgen is building a new facility in Ireland and expects to be fully operational later this year, creating the potential for long-term use of DehydraTECH for the pharmaceutical market.
Independent third-party testing has evidenced DehydraTECH’s ability to enhance the performance of a variety of pharmaceutical and wellness industry products and has led to a pre-Investigational New Drug (“IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to file DehydraTECH-CBD as a prospective registered treatment for hypertension this year (https://cnw.fm/M6RAk).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
